Skip to main content
Back
Watch Compare

Vivos Therapeutics, Inc.

Data quality: 100%
VVOS
NASDAQ Manufacturing Measuring & Analyzing Instruments
$1.47
▲ $0.12 (8.89%)
6 months return
—
Momentum
Neutral
5Y revenue growth
3.56%

Growth

Revenue Growth (5Y)
3.56%
Above sector avg (1.82%)
Revenue (1Y)8.91%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-480.76%
Below sector avg (-54.68%)
ROIC-68.18%
Net Margin-98.76%
Op. Margin-94.23%

Safety

Debt / Equity
3.31
Above sector avg (0.30)
Current Ratio0.78
Interest CoverageN/A

Valuation

PE (TTM|NTM)
-0.84 | -0.97
Above sector avg (-1.49)
P/B Ratio5.65
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Revenue grew 3.56% annually over 5 years — modest growth
Debt/Equity of 3.31 — high leverage
Negative free cash flow of -15.37 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 5.35%
Capital efficient — spends only 5.63% of revenue on capex

Price History

Financial Trends

Analyst Price Target

3 analysts
Buy
+240.1%
upside to target
Current
$1.47
Consensus Target
$5.00
$2.50
Low
$7.00
High
Forecast
Forward P/E
-0.97
Forward EPS
-$1.25
Est. Revenue
28.96 M

Earnings Surprises

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -$0.42 · Rev Est: 6.25 M
Q42024 Q12025 Q22025 Q32025 Q1 '26
Reported -$0.28 -$0.45 -$0.55 -$0.49 —
Estimate -$0.43 -$0.40 -$0.38 -$0.51 -$0.42
Surprise +34.88% -12.50% -44.74% +3.92% —

Growth

Rev 5Y: 3.56% · Earnings 1Y: N/A
Revenue Growth (1Y) 8.91% Revenue Growth (3Y) -3.15%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 3.56% Earnings Growth (5Y) N/A

Profitability

ROE: -480.76% · Net Margin: -98.76%
Revenue (TTM) 17.32 M Net Income (TTM) -17.10 M
ROE -480.76% ROA -66.19%
Gross Margin 55.73% Operating Margin -94.23%
Net Margin -98.76% Free Cash Flow (TTM) -15.37 M
ROIC -68.18% FCF Growth (3Y) N/A

Safety

D/E: 3.31 · Current: 0.78
Debt / Equity 3.31 Current Ratio 0.78
Interest Coverage N/A Asset Turnover 0.67
Working Capital -1.65 M Tangible Book Value -8.09 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -0.84 · EV/EBITDA: N/A
P/E Ratio -0.84 Forward P/E -0.97
P/B Ratio 5.65 P/S Ratio 0.83
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 0.49 Fwd Earnings Yield N/A
FCF Yield -107.43%
Market Cap 14.30 M Enterprise Value 19.60 M

Per Share

EPS: -1.77 · FCF/Share: -1.30
EPS (Diluted TTM) -1.77 Revenue / Share 1.46
FCF / Share -1.30 OCF / Share -1.22
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 89.84% · CapEx/Rev: 5.63%
CapEx / Revenue 5.63% FCF Conversion 89.84%
SBC-Adj. FCF -16.12 M Growth Momentum 5.35

Income Statement

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 15.03 M 13.80 M 16.02 M 16.89 M 13.07 M
Net Income -11.14 M -13.58 M -23.85 M -20.29 M -12.06 M
EPS (Diluted) -2.22 -11.14 — — —
Gross Profit 9.02 M 8.27 M 10.02 M 12.60 M 10.41 M
Operating Income -11.17 M -17.30 M -25.03 M -20.38 M -12.04 M
EBITDA — — — — —
R&D Expenses 100,000.0 100,000.0 200,000.0 — —
SG&A Expenses — — — — —
D&A 581,000.0 621,000.0 669,000.0 733,000.0 717,865.0
Interest Expense — — 14,000.0 14,000.0 96,681.0
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 15.28 M 10.73 M 13.72 M 33.69 M 25.33 M
Total Liabilities 7.33 M 10.32 M 8.92 M 8.15 M 8.41 M
Shareholders' Equity 7.95 M 411,000.0 4.80 M 25.54 M 16.92 M
Total Debt — — — 1.27 M 1.29 M
Cash & Equivalents 6.26 M 1.64 M 3.52 M 24.03 M 18.21 M
Current Assets 7.47 M 2.46 M 5.42 M 27.32 M 20.39 M
Current Liabilities 4.98 M 7.29 M 6.81 M 7.51 M 7.82 M

Peer Comparison

vs Manufacturing sector median (1605 peers)
Metric Stock Sector Median
P/E -0.8 -1.5
P/B 5.7 1.6
ROE % -480.8 -54.7
Net Margin % -98.8 -41.5
Rev Growth 5Y % 3.6 1.8
D/E 3.3 0.3